Data Supplement from A Bispecific HER2-Targeting FynomAb with Superior Antitumor Activity and Novel Mode of Action

Figure S1: Characterization of binding properties and thermal stability of Fynomer C12; Figure S2: Results of binding studies with C12-pertuzumab bispecific FynomAbs; Figure S3: Additional in vitro tumour growth inhibition studies with COVA208 on more HER2 positive cancer cell lines; Figure S4: Additional data on the induction of apoptosis in NCI-N87 cells by COVA208: dose-response curve of Caspase 3/7 activity, and Tunel assay; Figure S5: Expression data (heat map) of signalling mediators in response to treatment with COVA208, pertuzumab, or trastuzumab (RPPA analysis); Supplementary Table 1 listing expression data of 167 signaling proteins (phospho- and total proteins) in response to COVA208, pertuzumab or trastuzumab treatment of NCI-N87 cells in vitro.